{"doi":"10.1093\/eurjhf","coreId":"219905","oai":"oai:eprints.lse.ac.uk:37027","identifiers":["oai:eprints.lse.ac.uk:37027","10.1093\/eurjhf"],"title":"Cost-effectiveness of highly purified omega-3 polyunsaturated fatty acid ethyl esters in the treatment of chronic heart failure: results of Markov modelling in a UK setting","authors":["Cowie, Martin R.","Cure, Sandrine","Bianic, Florence","McGuire, Alistair","Goodall, Gordon","Tavazzi, Luigi"],"enrichments":{"references":[],"documentType":{"type":null}},"contributors":[],"datePublished":"2011-06","abstract":"Aims A recent randomized placebo-controlled clinical trial has reported reductions in mortality and hospitalizations in patients with chronic heart failure (CHF) who were prescribed highly purified omega-3 polyunsaturated fatty acid ethyl esters (n-3 PUFA). This study aimed at evaluating the cost and benefits associated with their use in the treatment of CHF in a UK setting.\\ud\nMethods and results Results from a recent clinical trial were used to develop a Markov model to project clinical outcomes while capturing relevant costs and patient quality of life. The model captured outcomes over a lifetime horizon from a UK National Health Service perspective, with direct costs accounted in 2009 GBP ((sic)) and discounted at 3.5% together with clinical benefits. Results are presented in terms of life expectancy, quality-adjusted life expectancy, direct costs, and incremental cost-effectiveness ratios. In addition to standard therapy, n-3 PUFA vs. placebo increased lifetime direct costs by (sic) 993 (approximate to E1150), with additional quality-adjusted life expectancy of 0.079 quality-adjusted life years (QALYs), and mean lifetime costs of (sic)12 636 (approximate to(sic)E14 600) per QALY gained. Probabilistic sensitivity analyses suggested a 60% likelihood of n-3 PUFA being regarded as cost-effective versus placebo at a willingness-to-pay threshold of (sic)30 000 (approximate to E34 600) per QALY gained","downloadUrl":"","fullTextIdentifier":null,"pdfHashValue":null,"publisher":"Oxford University Press","rawRecordXml":"<record><header><identifier>\n    \n    \n      oai:eprints.lse.ac.uk:37027<\/identifier><datestamp>\n      2011-06-29T14:01:32Z<\/datestamp><setSpec>\n      74797065733D4445505453:4C53452D5341<\/setSpec><setSpec>\n      74797065733D43454E54524553:4C53455F52435F3839<\/setSpec><\/header><metadata><oai_dc:dc xmlns:oai_dc=\"http:\/\/www.openarchives.org\/OAI\/2.0\/oai_dc\/\" xmlns:dc=\"http:\/\/purl.org\/dc\/elements\/1.1\/\" xmlns:xsi=\"http:\/\/www.w3.org\/2001\/XMLSchema-instance\" xsi:schemaLocation=\"http:\/\/www.openarchives.org\/OAI\/2.0\/oai_dc\/ http:\/\/www.openarchives.org\/OAI\/2.0\/oai_dc.xsd\" ><dc:relation>\n    \n      \n        http:\/\/eprints.lse.ac.uk\/37027\/<\/dc:relation><dc:title>\n        Cost-effectiveness of highly purified omega-3 polyunsaturated fatty acid ethyl esters in the treatment of chronic heart failure: results of Markov modelling in a UK setting<\/dc:title><dc:creator>\n        Cowie, Martin R.<\/dc:creator><dc:creator>\n        Cure, Sandrine<\/dc:creator><dc:creator>\n        Bianic, Florence<\/dc:creator><dc:creator>\n        McGuire, Alistair<\/dc:creator><dc:creator>\n        Goodall, Gordon<\/dc:creator><dc:creator>\n        Tavazzi, Luigi<\/dc:creator><dc:subject>\n        RA Public aspects of medicine<\/dc:subject><dc:description>\n        Aims A recent randomized placebo-controlled clinical trial has reported reductions in mortality and hospitalizations in patients with chronic heart failure (CHF) who were prescribed highly purified omega-3 polyunsaturated fatty acid ethyl esters (n-3 PUFA). This study aimed at evaluating the cost and benefits associated with their use in the treatment of CHF in a UK setting.\\ud\nMethods and results Results from a recent clinical trial were used to develop a Markov model to project clinical outcomes while capturing relevant costs and patient quality of life. The model captured outcomes over a lifetime horizon from a UK National Health Service perspective, with direct costs accounted in 2009 GBP ((sic)) and discounted at 3.5% together with clinical benefits. Results are presented in terms of life expectancy, quality-adjusted life expectancy, direct costs, and incremental cost-effectiveness ratios. In addition to standard therapy, n-3 PUFA vs. placebo increased lifetime direct costs by (sic) 993 (approximate to E1150), with additional quality-adjusted life expectancy of 0.079 quality-adjusted life years (QALYs), and mean lifetime costs of (sic)12 636 (approximate to(sic)E14 600) per QALY gained. Probabilistic sensitivity analyses suggested a 60% likelihood of n-3 PUFA being regarded as cost-effective versus placebo at a willingness-to-pay threshold of (sic)30 000 (approximate to E34 600) per QALY gained.<\/dc:description><dc:publisher>\n        Oxford University Press<\/dc:publisher><dc:date>\n        2011-06<\/dc:date><dc:type>\n        Article<\/dc:type><dc:type>\n        PeerReviewed<\/dc:type><dc:identifier>\n          Cowie, Martin R. and Cure, Sandrine and Bianic, Florence and McGuire, Alistair and Goodall, Gordon and Tavazzi, Luigi  (2011) Cost-effectiveness of highly purified omega-3 polyunsaturated fatty acid ethyl esters in the treatment of chronic heart failure: results of Markov modelling in a UK setting.  European Journal of Heart Failure, 13 (6).  pp. 681-689.  ISSN 1388-9842     <\/dc:identifier><dc:relation>\n        http:\/\/eurjhf.oxfordjournals.org\/<\/dc:relation><dc:relation>\n        10.1093\/eurjhf\/hfr023<\/dc:relation><\/oai_dc:dc><\/metadata><\/record>","journals":null,"language":null,"relations":["http:\/\/eprints.lse.ac.uk\/37027\/","http:\/\/eurjhf.oxfordjournals.org\/","10.1093\/eurjhf\/hfr023"],"year":2011,"topics":["RA Public aspects of medicine"],"subject":["Article","PeerReviewed"],"fullText":null}